173 related articles for article (PubMed ID: 23448822)
21. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies.
Kim M; Rostas S; Gabardi S
Am J Transplant; 2013 Jun; 13(6):1383-9. PubMed ID: 23617812
[TBL] [Abstract][Full Text] [Related]
22. Patient understanding of drug risks: an evaluation of medication guide assessments.
Knox C; Hampp C; Willy M; Winterstein AG; Dal Pan G
Pharmacoepidemiol Drug Saf; 2015 May; 24(5):518-25. PubMed ID: 25808393
[TBL] [Abstract][Full Text] [Related]
23. Risk Evaluation and Mitigation Strategies With Elements to Assure Safe Use: Alignment of the Goals With the Tools to Manage Risk.
Cronin M; Berger S; Seligman PJ
Ther Innov Regul Sci; 2014 Nov; 48(6):724-733. PubMed ID: 30227470
[TBL] [Abstract][Full Text] [Related]
24. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
Meyer BM
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
[TBL] [Abstract][Full Text] [Related]
25. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).
Huynh L; Toyserkani GA; Morrato EH
BMC Health Serv Res; 2021 Aug; 21(1):779. PubMed ID: 34362367
[TBL] [Abstract][Full Text] [Related]
26. Assessment of risk evaluation and mitigation strategies in oncology: summary of the oncology risk evaluation and mitigation strategies workshop.
Frame JN; Jacobson JO; Vogel WH; Griffith N; Wariabharaj D; Garg R; Zon R; Stephens CL; Bialecki AM; Bruinooge SS; Allen SL
J Oncol Pract; 2013 Mar; 9(2):e24-39. PubMed ID: 23814522
[TBL] [Abstract][Full Text] [Related]
27. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
Gudin J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
[TBL] [Abstract][Full Text] [Related]
28. Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?
Brooks MJ
Mayo Clin Proc; 2014 Dec; 89(12):1673-84. PubMed ID: 25441401
[TBL] [Abstract][Full Text] [Related]
29. What is the quality of drug safety information for patients: An analysis of REMS educational materials.
Chan HW; Russell AM; Smith MY
Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):969-978. PubMed ID: 30003610
[TBL] [Abstract][Full Text] [Related]
30. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
31. Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use.
Sarpatwari A; Brown BL; McGraw SA; Dejene SZ; Abdurrob A; Santiago Ortiz AJ; Kesselheim AS
JAMA Netw Open; 2022 Jan; 5(1):e2144386. PubMed ID: 35050352
[TBL] [Abstract][Full Text] [Related]
32. Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU).
Boudes PF
Drugs R D; 2017 Jun; 17(2):245-254. PubMed ID: 28160230
[TBL] [Abstract][Full Text] [Related]
33. Managing risk in developing transplant immunosuppressive agents: the new regulatory environment.
Gabardi S; Halloran PF; Friedewald J
Am J Transplant; 2011 Sep; 11(9):1803-9. PubMed ID: 21827622
[TBL] [Abstract][Full Text] [Related]
34. Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.
Childs L; Alexander E; Duong MT
Am J Health Syst Pharm; 2012 May; 69(10):885-9. PubMed ID: 22555085
[TBL] [Abstract][Full Text] [Related]
35. A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.
Sarpatwari A; Mitra-Majumdar M; Bykov K; Avorn J; Woloshin S; Toyserkani GA; LaCivita C; Manzo C; Zhou EH; Pinnow E; Dal Pan GJ; Gagne JJ; Huybrechts KF; Feldman WB; Chin K; Kesselheim AS
Drug Saf; 2021 Jul; 44(7):743-751. PubMed ID: 33904111
[TBL] [Abstract][Full Text] [Related]
36. Anatomy of Risk Evaluation and Mitigation Strategies (REMS).
Loeser KK; McKoy JM; Schumock GT
Cancer Treat Res; 2019; 171():93-105. PubMed ID: 30552659
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors.
Gabardi S; Olyaei A
Ann Pharmacother; 2012; 46(7-8):1054-64. PubMed ID: 22811345
[TBL] [Abstract][Full Text] [Related]
38. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
[TBL] [Abstract][Full Text] [Related]
39. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation.
Armenti VT; Daller JA; Constantinescu S; Silva P; Radomski JS; Moritz MJ; Gaughan WJ; McGrory CH; Coscia LA
Clin Transpl; 2006; ():57-70. PubMed ID: 18368705
[TBL] [Abstract][Full Text] [Related]
40. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].
Li Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
